You are leaving this site!

By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?

About Nabi-HB®

Discover how Nabi-HB® [Hepatitis B Immune Globulin (Human)] works and learn about product characteristics.

About Nabi-HB®

Understanding
Hepatitis B

Information and resources for patients with Hepatitis B.

About Hepatitis B

Information for
Healthcare Professionals

Learn about product manufacturing as well as clinical and safety data.

Read More

About Postexposure
Prophylaxis (PEP)

Learn more about PEP with NABI-HB® [Hepatitis B Immune Globulin (Human)].

About PEP

Important Safety Information for Nabi-HB®

Individuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB® [Hepatitis B Immune Globulin (Human)] or any other human immune globulin. Individuals who are deficient in IgA have the potential to develop antibodies against IgA and anaphylactic reactions.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB should be given only if the expected benefits outweigh the potential risks.

Nabi-HB is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents (e.g., viruses) and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Nabi-HB® [Hepatitis B Immune Globulin (Human)], must be administered only intramuscularly for post-exposure prophylaxis.

Vaccination with live virus vaccines (e.g., MMR) should be deferred until approximately three months after administration of Nabi-HB.

The most common adverse reactions associated with Nabi-HB in clinical trials were erythema and ache at the injection site as well as systemic reactions such as headache, myalgia, malaise, nausea and vomiting. No anaphylactic reactions with Nabi-HB have been reported.

Please see the full Prescribing Information for Nabi-HB® [Hepatitis B Immune Globulin (Human)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.